Nivolumab Plus Trastuzumab Deruxtecan Provides No Perceptible Clinical Benefit Over ADC Alone in Advanced HER2+ Breast Cancer

Via Peters

The addition of nivolumab to trastuzumab deruxtecan did not result in a marked clinical benefit in patients with locally advanced unresectable or metastatic HER2-positive breast cancer. The addition of nivolumab (Opdivo) to fam-trastuzumab deruxtecan-nxki (Enhertu) did not result in a marked clinical benefit in patients with locally advanced unresectable or […]